Cross-Resistance to Lincosamides, Streptogramins A, and Pleuromutins: Due to the Iṣa(C) Gene in *Streptococcus agalactiae* UCN70

Brigitte Malbruny, Anja M. Werno, David R. Murdoch, Roland Leclercq, and Vincent Cattoir

Service de Microbiologie and EA 2128, Relations Hôte et Microorganismes des Épithe liums, Hôpital Côte de Nacre, Université de Caen Basse-Normandie, Caen, France, and Microbiometry Unit, Canterbury Health Laboratories and University of Otago, Christchurch, New Zealand

Received 3 August 2010/Returned for modification 14 December 2010/Accepted 8 January 2011

*Streptococcus agalactiae* UCN70, isolated from a vaginal swab obtained in New Zealand, is resistant to lincosamides and streptogramins A (LSₐ phenotype) and also to tiamulin (a pleuromutilin). By whole-genome sequencing, we identified a 5,224-bp chromosomal extra-element that comprised a 1,479-bp open reading frame coding for an ABC protein (492 amino acids) 45% identical to Lsa(A), a protein related to intrinsic LSₐ resistance in *Enterococcus faecalis*. Expression of this novel gene, named *Iṣa(C)*, in *S. agalactiae* BM132 after cloning led to an increase in MICs of lincomycin (0.06 to 4 μg/ml), clindamycin (0.03 to 2 μg/ml), dalfopristin (2 to >32 μg/ml), and tiamulin (0.12 to 32 μg/ml), whereas no change in MICs of erythromycin (0.06 μg/ml), azithromycin (0.03 μg/ml), spiramycin (0.25 μg/ml), telithromycin (0.03 μg/ml), and quinupristin (8 μg/ml) was observed. The phenotype was renamed the LSₐ,P phenotype on the basis of cross-resistance to lincosamides, streptogramins A, and pleuromutins. This gene was also identified in similar genetic environments in 17 other *S. agalactiae* clinical isolates from New Zealand exhibiting the same LSₐ,P phenotype, whereas it was absent in susceptible *S. agalactiae* strains. Interestingly, this extra-element was bracketed by a 7-bp duplication of a target site (ATTAGAGA), suggesting that this structure was likely a mobile genetic element. In conclusion, we identified a novel gene, *Iṣa(C)*, responsible for the acquired LSₐ,P resistance phenotype in *S. agalactiae*. Dissection of the biochemical basis of resistance, as well as demonstration of *in vitro* mobilization of *Iṣa(C)*, remains to be performed.

*Streptococcus agalactiae* (group B streptococcus) is a leading cause of morbidity and mortality in neonates and pregnant women worldwide (14). It is also recognized as an emerging significant pathogen in nonpregnant adults, including elderly persons and patients with underlying conditions such as diabetes mellitus or immunosuppression (22). The clinical spectrum of *S. agalactiae* infection is broad and includes bacteremia, endocarditis, skin and soft tissue infections, respiratory and urinary tract infections, and joint and bone infections (23). Penicillin G and ampicillin represent the antimicrobial agents of choice for intrapartum antibiotic prophylaxis during labor and for treating invasive infections caused by *S. agalactiae* (14, 23). For patients who are allergic to penicillin, the recommended alternative drugs are macrolides or lincosamides (21). However, although *S. agalactiae* remains universally susceptible to penicillins, there is a significant and rising resistance to macrolides and lincosamides in both invasive and colonizing strains in many parts of the world, with reported prevalence values ranging from 7 to 32% and from 2 to 15%, respectively (26).

Even if macrolides, lincosamides, and streptogramins (referred to as MLS) are chemically distinct, they are classified in the same group due to their similar mechanisms of action to inhibit protein synthesis and their cross-resistance due to target modification (15). Macrolides are classified according to the number of atoms forming the lactone ring: 14 (e.g., erythromycin), 15 (e.g., azithromycin), or 16 (e.g., spiramycin). Telithromycin is a semisynthetic erythromycin A derivative, belonging to the ketolide subgroup, with enhanced activity against macrolide-resistant streptococci. Lincosamides comprise two representatives (lincomycin and clindamycin), whereas streptogramins correspond to a mixture of two compounds which act synergistically: streptogramins A (e.g., dalfopristin) and streptogramins B (e.g., quinupristin). Finally, pleuromutins (e.g., tiamulin) are also a class of protein synthesis inhibitors, mostly used in veterinary medicine, whose action and resistance mechanisms are similar to those of MLS (17).

In *S. agalactiae*, there are two major resistance mechanisms, namely, active efflux and target site modification (2, 5, 6, 8). The efflux pump is encoded by the *mef(A)* gene, whereas ribosomal alteration is mediated by a ribosomal methylase encoded by *erm(B)* and/or a specific *erm(A)* subtype formerly known as *erm(TR)*. Expression of *mef(A)* confers resistance to 14- and 15-membered ring macrolides (M phenotype) only, whereas expression of *erm(B)* and/or *erm(TR)* is responsible for cross-resistance to all macrolides, lincosamides, and streptogramins B (MLSₐ,p phenotype), and this resistance can be expressed constitutively or inducibly (15).

An unusual phenotype of resistance to lincosamides and streptogramins A (called the LSₐ phenotype) has been reported for 19 *S. agalactiae* clinical isolates collected in New Zealand (16, 26) and has also been identified in Asia (12, 27). However, the biochemical and genetic basis of this resistance has not been elucidated yet. For these 19 strains, antibiotics did not seem to be inactivated or exported, while no known acquired resistance genes were present (16). Although no plasmid and no conjugative transfer of resistance were detected, acquisition of re-
Bacterial strains and antimicrobial susceptibility testing. Nineteen S. agalactiae clinical isolates from New Zealand exhibiting an LS A phenotype (16). The aims of this study were (i) to identify the resistance determinant responsible for the LS A phenotype in S. agalactiae and (ii) to characterize the genetic support for this novel gene.

MATERIALS AND METHODS

Bacterial strains and antimicrobial susceptibility testing. Nineteen S. agalactiae clinical isolates from New Zealand exhibiting an LS A phenotype were studied (16, 26). The S. agalactiae UC70 isolate was recovered from a vaginal swab, while the other 18 clinical isolates were obtained from vaginal swabs (n = 8), urines (n = 2), and other sites (n = 8) (16). Thirteen isolates belonged to serotype III (including strain UC70), five belonged to serotype I, and one was nontypeable, while each serotype corresponded to a unique type by pulsed-field gel electrophoresis (genotypes A, B, and C) (16).

Whole-genome sequencing. Genomic DNA was extracted from mid-log-phase cultures of S. agalactiae UC70 by use of NucleoBond buffer set III and a NucleoBond AX-G 100 instrument (Macherey-Nagel, Hoerdt, France) following the manufacturer's instructions. High-throughput sequencing was performed by using a 454 Life Sciences (Roche) GS-FLX system (GATC Biotech, Konstanz, Germany). Shotgun sequencing led to an assembly of 83 contigs of 513 to 148,170 bp, with an average coverage of 5.224 bp per base of the genome. The nucleotide and deduced protein sequences for each contig were determined by the brot microsequencing method (tested range, 0.01 to 32 µg/ml) according to the manufacturer's instructions (3).

Identification of a novel lsa(C) gene in S. agalactiae UC70. This element was composed of four open reading frames (ORFs) (Fig. 1). One of the ORFs, with a length of 5,224 bp, putatively encoded for a 492-amino-acid (ca. 56-kDa) protein that displayed homology with ABC proteins and was a candidate for antimicrobial resistance. By analysis of the deduced amino acid sequence, two Walker A motifs (positions 38 to 46 and 342 to 350), two Walker B motifs (positions 138 to 142 and 443 to 448), two ABC signatures (positions 118 to 123 and 423 to 428), and two H-loop switches (positions 171 and 477) were identified (Fig. 2). Most ABC systems are involved in transport (importers or exporters) and share an organization of two hydrophobic transmembrane domains (TMDs) and two hydrophilic intracytoplasmic domains (13). The latter domains are characterized by the ATP-hydrolyzing domain (also referred to as the nucleotide-binding domain [NBD]), which comprises both Walker A and B motifs and the ABC signature (4, 13). Another category of ABC systems (class 2), those which lack detectable TMDs, is apparently not implicated in transport into S. agalactiae BM132 (9) electrocompetent cells, and transformants were selected on agar plates containing spectinomycin (180 µg/ml). The cloned DNA fragments of recombinant plasmids were sequenced on both strands by primer walking (GATC Biotech, Konstanz, Germany).

RESULTS AND DISCUSSION

TABLE 1. Deoxynucleotide primers used in this study

<table>
<thead>
<tr>
<th>Primer</th>
<th>Nucleotide sequence (5’ to 3’f)</th>
<th>Positiona</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>lsa-Ca-F</td>
<td>GGCTATTGAAAACCTTGTATTTG</td>
<td>5234–5256</td>
<td>Detection of lsa(C)</td>
</tr>
<tr>
<td>lsa-Ca-R</td>
<td>ACTGACATTATTCTTCTCGG</td>
<td>5643–5663</td>
<td>Cloning of lsa(C)</td>
</tr>
<tr>
<td>lsa-Ca-F-BamHI</td>
<td>ATCTTTTCTAGAATAGCATAAGG</td>
<td>5643–5663</td>
<td>Cloning of lsa(C)</td>
</tr>
<tr>
<td>lsa-Ca-R-ACTGACAATTTTTCTTCCGT</td>
<td>5643–5663</td>
<td>Cloning of lsa(C)</td>
<td></td>
</tr>
<tr>
<td>lsa-Ca-dw-F1</td>
<td>GATACATATAGGTTTTTGGGG</td>
<td>1623–1644</td>
<td>Determination of transcription start site</td>
</tr>
<tr>
<td>lsa-Ca-dw-R</td>
<td>ACTGACAATTTTTCTTCCGT</td>
<td>1623–1644</td>
<td>Determination of transcription start site</td>
</tr>
<tr>
<td>lsa-Ca-R</td>
<td>ACTGACAATTTTTCTTCCGT</td>
<td>1623–1644</td>
<td>Determination of transcription start site</td>
</tr>
</tbody>
</table>

a) Sa, Streptococcus agalactiae; F, forward primer; R, reverse primer; dw, downstream; up, upstream; int, internal; GSP, gene-specific primer.

b) Numbers in parentheses indicate the locations of the primers in Fig. 1.

c) Restriction sites are underlined.

d) Primer positions were determined according to the nucleotide sequence deposited in GenBank (accession no. HM90671).

REFERENCES

1. Bacterial genomic DNA was extracted from mid-log-phase cultures of S. agalactiae UC70 using a NucleoBond AX-G 100 instrument (Macherey-Nagel, Hoerdt, France) following the manufacturer's instructions. High-throughput sequencing was performed by using a 454 Life Sciences (Roche) GS-FLX system (GATC Biotech, Konstanz, Germany). Shotgun sequencing led to an assembly of 83 contigs of 513 to 148,170 bp, with an aggregate genome size of 2,136,339 bp and a 13.6× coverage of the genome. The nucleotide and deduced protein sequences for each contig were determined by the brot microsequencing method (tested range, 0.01 to 32 µg/ml) according to the manufacturer's instructions (3).

Whole-genome sequencing. Genomic DNA was extracted from mid-log-phase cultures of S. agalactiae UC70 by use of NucleoBond buffer set III and a NucleoBond AX-G 100 instrument (Macherey-Nagel, Hoerdt, France) following the manufacturer's instructions. High-throughput sequencing was performed by using a 454 Life Sciences (Roche) GS-FLX system (GATC Biotech, Konstanz, Germany). Shotgun sequencing led to an assembly of 83 contigs of 513 to 148,170 bp, with an aggregate genome size of 2,136,339 bp and a 13.6× average coverage of the genome. The nucleotide and deduced protein sequences for each contig were analyzed with the BlastN and BlastX programs, available at the National Center for Biotechnology Information website (http://blast.ncbi.nlm.nih.gov/Blast.cgi).

PCR amplification and sequencing. Bacterial genomic DNA was extracted using an Instagen Matrix kit (Bio-Rad, Marnes-la-Coquette, France). PCR experiments for detection and mapping were carried out under standard conditions, using primers synthesized by Eurogentec France SAS (Table 1). Purified PCR products were then directly sequenced with the same sets of primers in both directions (GATC Biotech, Konstanz, Germany).

Cloning experiments. The lsa(C) resistance determinant and its putative promoter region were amplified by PCR using primers modified to include BamHI and XbaI restriction sites (Table 1). The PCR fragment was then cloned into the shuttle vector pAT28 (25) in Escherichia coli TOP10 (Invitrogen, Cergy-Pontoise, France). Recombinant plasmids were then transformed by electroporation into S. agalactiae BM132 (9) electrocompetent cells, and transformants were selected on agar plates containing spectinomycin (180 µg/ml). The cloned DNA fragments of recombinant plasmids were sequenced on both strands by primer walking (GATC Biotech, Konstanz, Germany).

5′-RACE. Total RNAs were extracted from cultures of S. agalactiae transformants by using an Rnaeasy Protect minikit (Qiagen, Courtaboeuf, France). The promoter sequences were then determined by using a 5′ rapid amplification of cDNA ends (5′-RACE) kit (Invitrogen) according to the manufacturer's instructions, using different specific primers (Table 1).

Multiple alignment and phylogenetic analysis. Phylogenetic analysis was performed by using the neighbor-joining algorithm, using the multiple alignment software ClustalX (version 1.83), and the resulting tree was displayed with TreeView software (version 1.6.6).

Nucleotide sequence accession number. The nucleotide sequence of the lsa(C)-comprising genetic element has been deposited in the GenBank database under accession no. HM90671.
but rather, at least for some members, in mRNA translation and DNA repair (4). Class 2 also includes several proteins that confer resistance to macrolides and related compounds, such as Msr-like, Vga-like, and Lsa-like proteins (4). Interestingly, the novel ABC system contained no TMDs and showed 23 to 27%, 27 to 28%, and 45 to 53% amino acid identities with the aforementioned proteins, respectively. Like Msr(A) and other class 2 ABC systems (4, 20), the novel protein actually consisted of two NBDs fused into a single protein, explaining the two copies of Walker A and B motifs as well as those of the ABC signature (Fig. 2). Finally, the novel ABC transporter showed a G+C content of 31.8%, which is slightly lower than those of S. agalactiae (35.6%) and other streptococcal genomes (36.8 to 41.8%). The origin of this gene is likely low-G+C Gram-positive bacteria but remains unknown. Based on structural similarity, the novel gene was termed lsa(C) by the Nomenclature Center for MLS Resistance Genes (http://faculty.washington.edu/marylnr/).

**Drug resistance pattern conferred by the ABC protein Lsa(C).** A 2,079-bp DNA fragment comprising the novel gene and its putative promoter region was amplified with specific primers (Table 1) from the genomic DNA of S. agalactiae UCN70 and inserted into the shuttle vector pAT28. Once expressed in S. agalactiae BM132, it conferred a 64-fold increase in the MICs of lincomycin and clindamycin, a >16-fold increase of the MIC of dalfopristin, and a 256-fold increase of the MIC of tiamulin, whereas no change was observed in the MICs of macrolides and a ketolide (Table 2). The profile of cross-resistance to lincomycines, streptogramins A, and pleuromutilins, which we propose to designate the Lsa(C) phenotype, was similar to that of S. agalactiae UCN70, although the level of resistance to tiamulin was much lower in the parental strain (Table 2). A similar LS_{\text{S,P}} phenotype has already been reported for staphylococci with Vga(A) and its variant as well as with Vga(C) (7, 10). In Enterococcus faecalis, Lsa(A) is responsible for intrinsic resistance not only to lincosamides and streptogramins A (24) but also to pleuromutilins (our unpublished data). For Staphylococcus sciuri, an LSA phenotype was demonstrated to be related to the expression of the plasmid-mediated lsa(B) gene (11). Although Lsa(A) and other members of the class 2 ABC proteins are presumed to function as efflux pumps, the biochemical basis of resistance remains unclear. Two studies showed decreased accumulations of radiolabeled erythromycin and lincomycin in the presence of Msr(A) and Vga(A)_{\text{L,C}} respectively (18, 19). These proteins might recruit a membrane-spanning protein to cause active efflux of antibiotics, but no membrane partners have been identified yet (18, 19). Alternatively, a ribosome-related mechanism of resistance, such as ribosomal protection, could also be hypothesized. The accessibility of the antibiotic to its ribosomal target would be prevented by the ABC protein, reducing the driving force for import. Interestingly, Lsa-like proteins are homologous to the elongation factor eEF-3 from Saccharomyces cerevisiae, which is involved in the translation cycle of fungi (1). Another homologue of eEF-3 has also been identified in E. coli (RbaA, encoded by yhiF) and could be involved in translation by accelerating the release of decyl-tRNA from the ribosome (28).

**Genetic environment of lsa(C).** Comparison of the DNA sequence flanking the 5,224-bp extra-element of S. agalactiae UCN70 with the genome of S. agalactiae 2603V/R (GenBank accession no. AE009948) revealed that the element was inserted into the chromosome. The element was inserted precisely in an intergenic region lying between chromosomal genes encoding a protein belonging to the FstK/SpoIIIE family and a transcriptional regulator of the Cro/CI family. This element was composed of four ORFs (Fig. 1). orf1 putatively coded for a product (379 amino acids) exhibiting 94% identity and 96% similarity to a site-specific recombinase of the phage
integrase family from *S. agalactiae* 18RS21 (GenBank accession no. EAO62075). The orf2-encoded protein (344 amino acids) showed 92% identity and 95% similarity to a replication protein from *S. agalactiae* 18RS21 (GenBank accession no. EA062073). The product of *orf3* (97 amino acids) showed 95% identity and 95% similarity to a transcriptional regulator from *S. agalactiae* 18RS21 (GenBank accession no. EA061638). The fourth ORF (492 amino acids) corresponded to the *lsa(C)* gene. Interestingly, since this extra-element was bracketed by a 7-bp duplication of a target site (ATTAGAA), this structure was likely a mobile (or mobilized) genetic element. However, this structure did not resemble a typical transposon (absence of inverted repeats and of a transposase-encoding gene). The putative site-specific recombinase encoded by *orf1* might be related to the acquisition event, but this remains to be demonstrated. The promoter sequences for *lsa(C)* expression were determined using a 5'-RACE system (Fig. 1).

Distribution of *lsa(C)* among 18 other *S. agalactiae* isolates. The *lsa(C)* gene was detected by PCR in 17 of the 18 tested *S. agalactiae* isolates collected from New Zealand, with only the nontypeable (genotype C) strain being negative (16). For the 17 *lsa(C)*-positive isolates, PCR mapping showed that the *lsa(C)* gene was part of an element that was structurally indistinguishable (n = 14) or similar (n = 3) to the 5,224-bp extra-element of *S. agalactiae* UCN70. The absence of amplification of the *lsa(C)* gene from 50 lincosamide-susceptible isolates of *S. agalactiae* (data not shown) confirmed that Lsa(C) is not an indigenous ABC protein in this species.

FIG. 2. Amino acid sequence comparison of Lsa(C) and other related ABC proteins involved in MLS resistance, i.e., Lsa(A), Lsa(B), Msr(A), and Vga(A) (GenBank accession no. AT737525, AJ579365, X52085, and M90056, respectively). The two copies each of the Walker A and B motifs and ABC signatures are boxed, and H-loop switches are also indicated. Similarities in amino acid sequences are marked by asterisks (same amino acid), colons (strong similarity), and dots (family similarity). Multiple-sequence alignment was done with ClustalX 1.83 software.
In conclusion, we have identified a novel resistance determinant, Isa(C), responsible for the acquired LS\textsubscript{S} resistance phenotype in \textit{S. agalactiae} isolates from New Zealand. We also highlighted the role of this gene in resistance to pleuromutilins, and we proposed that the drug resistance phenotype be named the LS\textsubscript{S}P phenotype. PCR detection with specific primers may be useful for detection of this unusual resistance phenotype during epidemiological surveys. However, characterization of the biochemical mechanism of resistance needs further investigation. It also remains to be demonstrated if this chromosomal extra-element can be mobilized \textit{in vitro}.

ACKNOWLEDGMENT
This work was funded by a grant from the Ministère de l’Educaton Nationale et de la Recherche (EA2128), Université Caen Basse-Normandie, France.

REFERENCES
ERRATUM

Cross-Resistance to Lincosamides, Streptogramins A, and Pleuromutilins Due to the lsa(C) Gene in Streptococcus agalactiae UCN70

Brigitte Malbruny, Anja M. Werno, David R. Murdoch, Roland Leclercq, and Vincent Cattoir

Service de Microbiologie and EA 2128, Relations Hôte et Microorganismes des Épithéliums, Hôpital Côte de Nacre, Université de Caen Basse-Normandie, Caen, France, and Microbiology Unit, Canterbury Health Laboratories and University of Otago, Christchurch, New Zealand

Volume 55, no. 4, p. 1470–1474, 2011. Page 1471, column 1, line 25: “High-throughput sequencing was performed by using a 454 Life Sciences (Roche) GS-FLX system (GATC Biotech, Konstanz, Germany)” should read “High-throughput sequencing was performed by using a 454 Life Sciences (Roche) GS-FLX system (DNAVision, Charleroi, Belgium).”